MA29486B1 - Composes heterocycliques fusionnes - Google Patents
Composes heterocycliques fusionnesInfo
- Publication number
- MA29486B1 MA29486B1 MA30420A MA30420A MA29486B1 MA 29486 B1 MA29486 B1 MA 29486B1 MA 30420 A MA30420 A MA 30420A MA 30420 A MA30420 A MA 30420A MA 29486 B1 MA29486 B1 MA 29486B1
- Authority
- MA
- Morocco
- Prior art keywords
- substituted
- hydrocarbyl
- acyl
- sulfur
- fusioned
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/26—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/30—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
- C07D335/02—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
L'INVENTION CONCERNE UN ANTAGONISTE DE RÉCEPTEUR CRF COMPRENANT UN COMPOSÉ DE FORMULE (I). DANS CETTE FORMULE, R1 REPRÉSENTE UN HYDROCARBYLE ÉVENTUELLEMENT SUBSTITUÉ, UN GROUPE HÉTÉROCYCLIQUE À LIAISON C ÉVENTUELLEMENT SUBSTITUÉ, UN GROUPE HÉTÉROARYLE N-LIÉ ÉVENTUELLEMENT SUBSTITUÉ, UN CYANO OU UN ACYLE; R2 REPRÉSENTE UN HYDROCARBYLE CYCLIQUE ÉVENTUELLEMENT SUBSTITUÉ OU UN GROUPE HÉTÉROCYCLIQUE ÉVENTUELLEMENT SUBSTITUÉ; X REPRÉSENTE DE L'OXYGÈNE, DU SOUFRE OU -NR3- (R3 REPRÉSENTANT UN HYDROGÈNE, UN HYDROCARBYLE ÉVENTUELLEMENT SUBSTITUÉ OU UN ACYLE); Y1, Y2 ET Y3 REPRÉSENTANT CHACUN UN CARBONE OU UN AZOTE ÉVENTUELLEMENT SUBSTITUÉ, À CONDITION QU'UN OU MOINS DE Y1, Y2 ET Y3 REPRÉSENTENT UN AZOTE; ET Z CONSISTE EN UNE LIAISON, -CO-, UN OXYGÈNE, UN SOUFRE, -SO-, -SO2-, -NR4-, -NR4-ALK-, -CONR4- OU -NR4CO- (ALK REPRÉSENTANT UN ALKYLÈNE EN C3-4 ÉVENTUELLEMENT SUBSTITUÉ ET R4 REPRÉSENTANT UN HYDROGÈNE, UN HYDROCARBYLE ÉVENTUELLEMENT SUBSTITUÉ OU UN ACYLE). L'INVENTION CONCERNE ÉGALEMENT UN SEL OU UN PROMÉDICAMENT DE CE COMPOSÉ.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US67511305P | 2005-04-27 | 2005-04-27 | |
US74210105P | 2005-12-02 | 2005-12-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA29486B1 true MA29486B1 (fr) | 2008-05-02 |
Family
ID=37215421
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA30420A MA29486B1 (fr) | 2005-04-27 | 2007-11-26 | Composes heterocycliques fusionnes |
Country Status (19)
Country | Link |
---|---|
US (1) | US8163935B2 (fr) |
EP (1) | EP1874736A4 (fr) |
JP (1) | JP5061097B2 (fr) |
KR (1) | KR101368037B1 (fr) |
AR (1) | AR053859A1 (fr) |
AU (1) | AU2006241210B2 (fr) |
BR (1) | BRPI0610150A2 (fr) |
CA (1) | CA2605453A1 (fr) |
CR (1) | CR9421A (fr) |
GE (1) | GEP20104962B (fr) |
IL (1) | IL186407A (fr) |
MA (1) | MA29486B1 (fr) |
MX (1) | MX2007013154A (fr) |
NO (1) | NO20075936L (fr) |
NZ (1) | NZ562235A (fr) |
PE (1) | PE20061377A1 (fr) |
RU (1) | RU2408586C2 (fr) |
TW (1) | TWI370820B (fr) |
WO (1) | WO2006116412A2 (fr) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008543841A (ja) | 2005-06-14 | 2008-12-04 | シェーリング コーポレイション | 大環状複素環式アスパルチルプロテアーゼインヒビター |
WO2008051533A2 (fr) | 2006-10-25 | 2008-05-02 | Takeda Pharmaceutical Company Limited | Composés de benzimidazole |
EP2125753A1 (fr) * | 2006-12-29 | 2009-12-02 | Takeda Pharmaceutical Company Limited | Composes heterocycliques lies par fusion developpant une activite antagoniste au crf |
UY31604A1 (es) * | 2008-01-22 | 2009-08-31 | Compuestos tricíclicos y uso de los mismos | |
UY32045A (es) * | 2008-08-12 | 2010-03-26 | Takeda Pharmaceutical | Compuesto amida |
WO2010032461A1 (fr) * | 2008-09-17 | 2010-03-25 | 武田薬品工業株式会社 | Composé à cycles fusionnés contenant de l’azote |
MX2011003239A (es) | 2008-09-26 | 2011-04-28 | Merck Sharp & Dohme | Nuevos derivados de bencimidazol ciclicos utiles como agentes anti-diabeticos. |
EP2348857B1 (fr) | 2008-10-22 | 2016-02-24 | Merck Sharp & Dohme Corp. | Nouveaux dérivés de benzimidazole cycliques utiles comme agents anti-diabétiques |
MX2011004505A (es) | 2008-10-29 | 2011-05-31 | Merck Sharp & Dohme | Derivados novedosos de bencimidazol ciclico, utiles como agentes antidiabeticos. |
CA2741672A1 (fr) | 2008-10-31 | 2010-05-06 | Merck Sharp & Dohme Corp. | Nouveaux agents antidiabetiques utiles avec des derives de benzimidazole cycliques |
EP2518054A1 (fr) | 2009-12-24 | 2012-10-31 | Takeda Pharmaceutical Company Limited | Composé amide |
US8895596B2 (en) | 2010-02-25 | 2014-11-25 | Merck Sharp & Dohme Corp | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
MA34397B1 (fr) | 2010-07-02 | 2013-07-03 | Gilead Sciences Inc | Dérivés d'acide napht-2-ylacétique dans le traitement du sida |
PE20130525A1 (es) | 2010-07-02 | 2013-05-05 | Gilead Sciences Inc | Derivados de acido 2 quinolinil acetico como compuestos antivirales frente a vih |
CA2833377C (fr) | 2011-04-21 | 2019-02-12 | Gilead Sciences, Inc. | Composes benzothiazoles et leur utilisation pharmaceutique |
KR101778354B1 (ko) | 2011-08-18 | 2017-09-13 | 니뽄 신야쿠 가부시키가이샤 | 헤테로환 유도체 및 의약 |
US9376392B2 (en) | 2012-01-04 | 2016-06-28 | Gilead Sciences, Inc. | 2-(tert-butoxy)-2-(7-methylquinolin-6-yl) acetic acid derivatives for treating AIDS |
US9284323B2 (en) | 2012-01-04 | 2016-03-15 | Gilead Sciences, Inc. | Naphthalene acetic acid derivatives against HIV infection |
PE20141558A1 (es) | 2012-04-20 | 2014-11-06 | Gilead Sciences Inc | Derivados de acido benzotiazol-6-il acetico y su uso para tratar una infeccion por vih |
EP3096756B1 (fr) | 2014-01-21 | 2024-06-12 | Neurocrine Biosciences, Inc. | Antagonistes du récepteur crf1 pour le traitement de l'hyperplasie adrénale congénitale |
JO3705B1 (ar) | 2014-11-26 | 2021-01-31 | Bayer Pharma AG | إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية |
EP3195865A1 (fr) | 2016-01-25 | 2017-07-26 | Bayer Pharma Aktiengesellschaft | Combinaisons d'inhibiteurs d'irak4 et inhibiteurs de btk |
US20180289685A1 (en) | 2015-04-30 | 2018-10-11 | Bayer Pharma Aktiengesellschaft | Combinations of inhibitors of irak4 with inhibitors of btk |
JP6837052B2 (ja) * | 2016-03-09 | 2021-03-03 | 日本曹達株式会社 | ピリジン化合物およびその用途 |
EP3219329A1 (fr) | 2016-03-17 | 2017-09-20 | Bayer Pharma Aktiengesellschaft | Combinaisons de copanlisib |
AU2017272505B9 (en) | 2016-06-01 | 2021-10-28 | Bayer Animal Health Gmbh | Substituted indazoles useful for treatment and prevention of allergic and/or inflammatory diseases in animals |
MA45089A (fr) | 2016-06-01 | 2019-04-10 | Bayer Pharma AG | Utilisation d'indazoles 2-substitués pour le traitement et la prophylaxie de maladies auto-immunes |
CN110248938A (zh) | 2016-11-23 | 2019-09-17 | 拜耳作物科学股份公司 | 用作农药的2-[3-(烷基磺酰基)-2h-吲唑-2-基]-3h-咪唑并[4,5-b]吡啶衍生物和类似化合物 |
Family Cites Families (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997048697A1 (fr) | 1996-06-19 | 1997-12-24 | Rhone-Poulenc Rorer Limited | Composes azabicycliques substitues et leur utilisation en tant qu'inhibiteurs de la production de tnf et de la photodiesterase cyclique d'amp |
WO1998005327A1 (fr) * | 1996-08-05 | 1998-02-12 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Composes aromatiques substitues |
US6365589B1 (en) * | 1998-07-02 | 2002-04-02 | Bristol-Myers Squibb Pharma Company | Imidazo-pyridines, -pyridazines, and -triazines as corticotropin releasing factor antagonists |
US6124463A (en) * | 1998-07-02 | 2000-09-26 | Dupont Pharmaceuticals | Benzimidazoles as corticotropin release factor antagonists |
US6376664B1 (en) * | 1999-03-17 | 2002-04-23 | The Ohio State University | Cyclic bis-benzimidazole ligands and metal complexes thereof |
SI1194425T1 (sl) * | 1999-06-23 | 2005-12-31 | Sanofi Aventis Deutschland | Substituirani benzimidazoli |
SK18942001A3 (sk) | 1999-06-28 | 2002-10-08 | Janssen Pharmaceutica N. V. | Inhibítory replikácie respiračného syncytiálneho vírusu |
AU7314200A (en) * | 1999-09-17 | 2001-04-24 | Yamanouchi Pharmaceutical Co., Ltd. | Benzimidazole derivatives |
WO2001021160A2 (fr) | 1999-09-23 | 2001-03-29 | Axxima Pharmaceuticals Aktiengesellschaft | Derives de carboxamide, inhibiteurs selectifs d'agents pathogenes |
US6506769B2 (en) * | 1999-10-06 | 2003-01-14 | Boehringer Ingelheim Pharmaceuticals, Inc. | Heterocyclic compounds useful as inhibitors of tyrosine kinases |
EP1222187B1 (fr) | 1999-10-06 | 2004-09-22 | Boehringer Ingelheim Pharmaceuticals Inc. | Composes heterocycliques utiles comme inhibiteurs de tyrosine kinases |
EP1303272B1 (fr) | 2000-06-21 | 2008-02-13 | F. Hoffmann-La Roche Ag | Derives de benzothiazole pour le traitement de la maladie d'alzheimer et de la maladie de parkinson |
ES2299501T3 (es) | 2000-08-11 | 2008-06-01 | Boehringer Ingelheim Pharmaceuticals Inc. | Compuestos heterociclicos utiles como inhibidores de tirosina-quinasas. |
DE10060292A1 (de) * | 2000-12-05 | 2002-06-20 | Aventis Pharma Gmbh | Verwendung substituierter Benzimidazole zur Herstellung eines Medikaments zur Behandlung von Krankheiten, welche durch Inhibierung des Na+/H+-Austauschers beeinflusst werden können und sie enthaltendes Medikament |
US20020146469A1 (en) | 2000-12-20 | 2002-10-10 | Benjamin Wiegand | Methods for reducing chronic stress in mammals |
CN1531530A (zh) * | 2001-02-05 | 2004-09-22 | 罗奇维生素股份公司 | 新的2-苯并噁唑基苯衍生物及其用作紫外线掩蔽剂的用途 |
US7030150B2 (en) | 2001-05-11 | 2006-04-18 | Trimeris, Inc. | Benzimidazole compounds and antiviral uses thereof |
US6734179B2 (en) | 2001-12-12 | 2004-05-11 | Hoffmann-La Roche Inc. | Benzothiazoles |
GB0203045D0 (en) | 2002-02-08 | 2002-03-27 | Johnson & Johnson Consumer | Method of afefecting sleep and sleep-related behaviours |
US8299108B2 (en) * | 2002-03-29 | 2012-10-30 | Novartis Ag | Substituted benzazoles and methods of their use as inhibitors of raf kinase |
IL164302A0 (en) | 2002-03-29 | 2005-12-18 | Chiron Corp | Substituted benzazoles and use thereof as raf kinase inhibitors |
US7049333B2 (en) * | 2002-06-04 | 2006-05-23 | Sanofi-Aventis Deutschland Gmbh | Substituted thiophenes: compositions, processes of making, and uses in disease treatment and diagnosis |
EP1551811A1 (fr) * | 2002-10-17 | 2005-07-13 | Amgen Inc. | Derives de benzimidazoles et utilisation de ceux-ci en tant que ligands du recepteur vanilloide |
AU2003294249A1 (en) | 2002-11-08 | 2004-06-03 | Trimeris, Inc. | Hetero-substituted benzimidazole compounds and antiviral uses thereof |
WO2004099148A1 (fr) | 2003-05-09 | 2004-11-18 | Pharmacia & Upjohn Company Llc | Derives pyrimidiques substitues |
US20040242560A1 (en) * | 2003-05-22 | 2004-12-02 | Aventis Pharma Deutschland Gmbh | Process for synthesizing heterocyclic compounds |
CA2530081A1 (fr) | 2003-07-01 | 2005-01-13 | Merck & Co., Inc. | Compositions ophtalmiques destinees au traitement d'hypertension oculaire |
US20050042212A1 (en) * | 2003-07-24 | 2005-02-24 | Nanda Steven A. | Method of reducing CRF receptor mRNA |
DE10337942A1 (de) * | 2003-08-18 | 2005-03-17 | Merck Patent Gmbh | Aminobenzimidazolderivate |
DE10349587A1 (de) * | 2003-10-24 | 2005-05-25 | Merck Patent Gmbh | Benzimidazolylderivate |
CA2543707A1 (fr) * | 2003-10-31 | 2005-05-19 | Takeda Pharmaceutical Company Limited | Composes heterocycliques accoles contenant de l'azote |
WO2005058870A1 (fr) | 2003-12-18 | 2005-06-30 | Tibotec Pharmaceuticals Ltd. | Derives amino-benzimidazoles utilises en tant qu'inhibiteurs de la replication du virus syncytial respiratoire |
AR046959A1 (es) | 2003-12-18 | 2006-01-04 | Tibotec Pharm Ltd | Morfolinilo que contiene bencimidazoles como inhibidores de la replicacion del virus sincitial respiratorio |
DK1723136T3 (da) | 2003-12-18 | 2011-06-27 | Tibotec Pharm Ltd | Piperidinamino-benzimidazol-derivat som inhibitorer af replikation af respiratorisk syncytial virus |
AU2004312001B2 (en) | 2003-12-19 | 2009-08-27 | Merck & Co., Inc. | Cyclic guanidines, compositions containing such compounds and methods of use |
US7470712B2 (en) | 2004-01-21 | 2008-12-30 | Bristol-Myers Squibb Company | Amino-benzazoles as P2Y1 receptor inhibitors |
EP1716136A1 (fr) | 2004-02-11 | 2006-11-02 | Ulkar Kimya Sanayii Ve Ticaret A.S. | Pyridine benzimidazole sulphoxides de grande pureté |
WO2006078907A1 (fr) * | 2005-01-20 | 2006-07-27 | Amgen Inc. | Dérivés de benzimidazole substitué en position 2 servant de ligands de récepteur vanilloïde et utilisation de ceux-ci dans des traitements |
EP2457901A1 (fr) | 2005-03-14 | 2012-05-30 | High Point Pharmaceuticals, LLC | Dérivés de benzazole, compositions et procédés d'utilisation en tant qu'inhibiteurs de secrétase B |
WO2008013270A1 (fr) | 2006-07-28 | 2008-01-31 | Ono Pharmaceutical Co., Ltd. | Procédé de diagnostic d'une maladie neuropsychiatrique |
EP2125753A1 (fr) * | 2006-12-29 | 2009-12-02 | Takeda Pharmaceutical Company Limited | Composes heterocycliques lies par fusion developpant une activite antagoniste au crf |
UY31604A1 (es) * | 2008-01-22 | 2009-08-31 | Compuestos tricíclicos y uso de los mismos | |
UY32045A (es) * | 2008-08-12 | 2010-03-26 | Takeda Pharmaceutical | Compuesto amida |
-
2006
- 2006-04-21 TW TW095114290A patent/TWI370820B/zh not_active IP Right Cessation
- 2006-04-26 AU AU2006241210A patent/AU2006241210B2/en not_active Ceased
- 2006-04-26 PE PE2006000437A patent/PE20061377A1/es not_active Application Discontinuation
- 2006-04-26 KR KR1020077024873A patent/KR101368037B1/ko not_active IP Right Cessation
- 2006-04-26 WO PCT/US2006/015646 patent/WO2006116412A2/fr active Application Filing
- 2006-04-26 RU RU2007143966/04A patent/RU2408586C2/ru not_active IP Right Cessation
- 2006-04-26 GE GEAP200610339A patent/GEP20104962B/en unknown
- 2006-04-26 AR ARP060101661A patent/AR053859A1/es unknown
- 2006-04-26 US US11/919,435 patent/US8163935B2/en not_active Expired - Fee Related
- 2006-04-26 EP EP06751379A patent/EP1874736A4/fr not_active Withdrawn
- 2006-04-26 JP JP2008509045A patent/JP5061097B2/ja not_active Expired - Fee Related
- 2006-04-26 BR BRPI0610150-0A patent/BRPI0610150A2/pt not_active IP Right Cessation
- 2006-04-26 NZ NZ562235A patent/NZ562235A/xx not_active IP Right Cessation
- 2006-04-26 CA CA002605453A patent/CA2605453A1/fr not_active Abandoned
- 2006-04-26 MX MX2007013154A patent/MX2007013154A/es active IP Right Grant
-
2007
- 2007-10-07 IL IL186407A patent/IL186407A/en not_active IP Right Cessation
- 2007-10-08 CR CR9421A patent/CR9421A/es unknown
- 2007-11-19 NO NO20075936A patent/NO20075936L/no not_active Application Discontinuation
- 2007-11-26 MA MA30420A patent/MA29486B1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
TW200716639A (en) | 2007-05-01 |
PE20061377A1 (es) | 2007-01-18 |
AR053859A1 (es) | 2007-05-23 |
JP2008539247A (ja) | 2008-11-13 |
IL186407A (en) | 2014-04-30 |
KR101368037B1 (ko) | 2014-02-26 |
US8163935B2 (en) | 2012-04-24 |
WO2006116412A8 (fr) | 2007-03-01 |
CA2605453A1 (fr) | 2006-11-02 |
JP5061097B2 (ja) | 2012-10-31 |
MX2007013154A (es) | 2008-01-21 |
WO2006116412A2 (fr) | 2006-11-02 |
NO20075936L (no) | 2007-11-19 |
AU2006241210B2 (en) | 2011-11-17 |
EP1874736A2 (fr) | 2008-01-09 |
CR9421A (es) | 2007-12-12 |
EP1874736A4 (fr) | 2008-08-20 |
GEP20104962B (en) | 2010-04-26 |
NZ562235A (en) | 2010-03-26 |
IL186407A0 (en) | 2008-01-20 |
RU2007143966A (ru) | 2009-06-10 |
RU2408586C2 (ru) | 2011-01-10 |
AU2006241210A1 (en) | 2006-11-02 |
US20090312383A1 (en) | 2009-12-17 |
BRPI0610150A2 (pt) | 2012-09-25 |
TWI370820B (en) | 2012-08-21 |
WO2006116412A3 (fr) | 2007-06-28 |
KR20080000625A (ko) | 2008-01-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA29486B1 (fr) | Composes heterocycliques fusionnes | |
MA31714B1 (fr) | Derive de pyrazole substitue | |
Wang et al. | Discovery of novel pyrazolo [1, 5-a] pyrimidines as potent pan-Pim inhibitors by structure-and property-based drug design | |
NO20076018L (no) | Lagringsstabile opplosninger av optiske hvitemidler | |
Rueeger et al. | Design, synthesis and SAR of a series of 2-substituted 4-amino-quinazoline neuropeptide Y Y5 receptor antagonists | |
Schirmeister et al. | Evaluation of dipeptide nitriles as inhibitors of rhodesain, a major cysteine protease of Trypanosoma brucei | |
TW200510381A (en) | Novel 2-pyridinecarboxamide derivatives | |
NO20062633L (no) | Pyrazolderivater som proteinkinasemodulatorer | |
TW200611907A (en) | Fused heterocyclic compound | |
ATE496035T1 (de) | Stickstoffenthaltende heterocyclische verbindungen | |
ATE556058T1 (de) | 1-(2h)-isochinolonderivat | |
UA81468C2 (en) | Heteroarylcarbamoylbenzene derivatives | |
CL2004000016A1 (es) | Compuesto derivado de cloruro de 4-amino-2-butenoilo o una sal farmaceuticamente aceptable del mismo; procedimiento para preparar dicho compuesto, util como intermediario en la sintesis de compuestos inhibidores de proteina quinasa tirosina. | |
NO20064200L (no) | Fremgangsmate for syntese av en CXCR4-antagonist | |
BRPI0619894B8 (pt) | composto de amina e composição farmacêutica | |
NO20072753L (no) | 3-Etylidenhydrazinosubstituerte heterocykliske forbindelser som trombopoietinreseptoraktivatorer | |
ATE449082T1 (de) | (3,4-dihydro-chinazolin-2-yl)-(2-aryloxy-ethyl) amine mit aktivität am 5-ht-rezeptor | |
NO20076402L (no) | Imaging 18F or 11C-labelled alkylthiophenyl guanidines | |
MA35893B1 (fr) | Dérivés d'amide hétérocyclique comme antagonistes du récepteur p2x7 | |
ITMI20041566A1 (it) | "trpv1 agonisti, formulazioni che li contengono e loro usi" | |
Chandra et al. | Theoretical study on protonated and deprotonated 5-substituted uracil derivatives and their complexes with water | |
TW200626130A (en) | 5-membered heterocycle derivatives | |
DK1325923T3 (da) | Cephem-forbindelser og ESBL-detekterende reagenser indeholdende disse | |
DE602006010702D1 (de) | Homomorpholinoxazolidinone als antibakterielle mittel | |
ECSP066810A (es) | Derivados de carbamato de 2h- ó 3h-benzo[e]indazol-1-ilo, su preparación y su aplicación en terapéutica |